ProShare Advisors LLC Sells 17,708 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

ProShare Advisors LLC reduced its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 15.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,203 shares of the medical instruments supplier’s stock after selling 17,708 shares during the quarter. ProShare Advisors LLC owned 0.43% of LeMaitre Vascular worth $7,916,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co grew its holdings in shares of LeMaitre Vascular by 44.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after buying an additional 6,875 shares during the last quarter. Quantbot Technologies LP grew its holdings in shares of LeMaitre Vascular by 1,001.4% during the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after buying an additional 6,669 shares during the last quarter. Ranger Investment Management L.P. grew its holdings in shares of LeMaitre Vascular by 1.5% during the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after buying an additional 13,681 shares during the last quarter. Congress Asset Management Co. MA grew its holdings in shares of LeMaitre Vascular by 12.0% during the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after buying an additional 71,411 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of LeMaitre Vascular by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 0.3 %

LMAT opened at $91.13 on Wednesday. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 60.35, a PEG ratio of 2.28 and a beta of 0.88. LeMaitre Vascular, Inc. has a twelve month low of $44.27 and a twelve month high of $92.90. The company’s 50-day moving average price is $87.02 and its two-hundred day moving average price is $78.47.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The firm had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. During the same period in the previous year, the company earned $0.37 earnings per share. The company’s quarterly revenue was up 11.4% on a year-over-year basis. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 42.38%.

Analyst Ratings Changes

LMAT has been the topic of several analyst reports. Roth Mkm restated a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a report on Friday, May 31st. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Barrington Research restated an “outperform” rating and set a $92.00 price target on shares of LeMaitre Vascular in a report on Friday, September 20th. Finally, JMP Securities boosted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $94.40.

Insider Activity

In other news, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The disclosure for this sale can be found here. Insiders have sold a total of 43,251 shares of company stock valued at $3,714,994 over the last quarter. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.